Blindness News and Research

RSS

Researchers reveal why RB1 gene mutations primarily cause retinoblastomas in children

Retinoblastoma is a childhood retinal tumor usually affecting children one to two years of age. Although rare, it is the most common malignant tumor of the eye in children.

25 Sep 2014

Celgene Global Health, DNDi expand partnership to identify new drug candidates for NTDs

Celgene Global Health, a division of Celgene Corporation, and the Drugs for Neglected Diseases initiative strengthen their collaboration with a four-year Research Collaboration Agreement to identify and optimize new drug candidates for the treatment of neglected tropical diseases (NTDs).

24 Sep 2014

Dynamical glucometry may uncover new ways of understanding diabetes

For millions of people in the United States living with Type 1 or Type 2 diabetes, measuring the daily rise and fall of blood glucose (sugar) is a way of life.

24 Sep 2014

Diabetes rates among U.S. adults stabilizing

Following a doubling of the incidence and prevalence of diabetes in the U.S. from 1990-2008, new data suggest a plateauing of the rate between 2008 and 2012 for adults, however the incidence continued to increase in Hispanic and non-Hispanic black adults, according to a study in the September 24 issue of JAMA.

24 Sep 2014

EYLEA Injection gets approval in Japan for treatment of myopic CNV

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV).

22 Sep 2014

Research roundup: Home health nurses' workloads; readmissions at the VA; SHOP choices

In anticipation of next year's premium announcements and given some information already made public, concerns have surfaced about the potential for double-digit percent increases in nongroup and small-group health insurance premiums. This analysis shows that, although average annual increases in small-group premiums over the past 13 years averaged roughly 5.5 percent, double-digit average premium increases are common for states and large metropolitan areas.

22 Sep 2014

UVA Center for Telehealth receives 2014 Governor's Technology Award

The University of Virginia Center for Telehealth received a 2014 Governor's Technology Award for making it easier to access high-quality care and health education for patients across Virginia.

21 Sep 2014

Envision Conference 2014 kicks off with presentation of two prestigious awards

Envision announced today that Second Sight Medical Products, Inc., a San Fernando Valley, Calif.-based medical device manufacturer, and Janet Sunness, M.D., Medical Director of Richard E. Hoover Low Vision Rehabilitation Services at Greater Baltimore Medical Center in Towson, Md., were named the 2014 recipients, respectively, of the Envision Oculus Award and Envision Award in Low Vision Research, two prestigious honors acknowledging substantial contributions to furthering research and facilitating collaborative efforts toward addressing low vision and the conditions that cause it.

19 Sep 2014

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).

16 Sep 2014

Cochrane Review rejects safety concerns regarding cheap alternative drug for treating eye disease

Health policies which favour using ranibizumab for treating eye disease in older people over safety concerns for a cheaper alternative should take account of a new Cochrane Review published today.

16 Sep 2014

New research shows statins could reduce common diabetes complications

The development of common diabetes complications that can lead to blindness and amputations could be reduced by taking statins, indicates new research published in The Lancet Diabetes & Endocrinology.

11 Sep 2014

Professor receives award for development of anti-angiogenic therapy for retinal disease

Napoleone Ferrara, MD, distinguished professor of pathology and distinguished adjunct professor of ophthalmology at the University of California, San Diego School of Medicine and senior deputy director for basic sciences at UC San Diego Moores Cancer Center, was named today as one of seven recipients of the Ant-nio Champalimaud Vision Award in Lisbon, Portugal.

11 Sep 2014

BioLight Life Sciences declares first sale of IOPtiMate system in Hong Kong

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announces the first sale of an IOPtiMate™ system in Hong Kong.

10 Sep 2014

Scientists identify how molecular motor essential for human development works

Another mystery of the human body has been solved by scientists who have identified how a molecular motor essential for human development works.

10 Sep 2014

Transparency Life receives SBIR program grant to fund Phase 2a proof-of-concept study for MS

Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS).

8 Sep 2014

Treating wet AMD with gold nanoparticles: an interview with Jim Taylor, CEO, Oraya Therapeutics

Wet AMD is characterized by abnormal growth of blood vessels in the macula (the area of the eye containing vision-enabling photoreceptors), and is responsible for the vast majority of severe vision loss in the industrialized world.

4 Sep 2014

Using molecular imaging probes diabetic retinopathy can be detected at molecular level

A new study published in the September issue of The FASEB Journal, identifies a novel strategy to diagnose the leading cause of blindness in adults, diabetic retinopathy, before irreversible structural damage has occurred.

3 Sep 2014

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

Antisense Therapeutics Limited is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly.

2 Sep 2014

Tiny eye implant enables patients to battle glaucoma

For the 2.2 million Americans battling glaucoma, the main course of action for staving off blindness involves weekly visits to eye specialists who monitor - and control - increasing pressure within the eye.

27 Aug 2014

Penn Medicine launches CAROT to build novel therapies for retinal and ocular disorders

The Perelman School of Medicine at the University of Pennsylvania has launched the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to build on its previous success developing novel therapies for the personalized diagnosis and treatment of retinal and ocular disorders.

22 Aug 2014

Blindness News and Research

Researchers reveal why RB1 gene mutations primarily cause retinoblastomas in children

Celgene Global Health, DNDi expand partnership to identify new drug candidates for NTDs

Dynamical glucometry may uncover new ways of understanding diabetes

Diabetes rates among U.S. adults stabilizing

EYLEA Injection gets approval in Japan for treatment of myopic CNV

Research roundup: Home health nurses' workloads; readmissions at the VA; SHOP choices

UVA Center for Telehealth receives 2014 Governor's Technology Award

Envision Conference 2014 kicks off with presentation of two prestigious awards

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Cochrane Review rejects safety concerns regarding cheap alternative drug for treating eye disease

New research shows statins could reduce common diabetes complications

Professor receives award for development of anti-angiogenic therapy for retinal disease

BioLight Life Sciences declares first sale of IOPtiMate system in Hong Kong

Scientists identify how molecular motor essential for human development works

Transparency Life receives SBIR program grant to fund Phase 2a proof-of-concept study for MS

Treating wet AMD with gold nanoparticles: an interview with Jim Taylor, CEO, Oraya Therapeutics

Using molecular imaging probes diabetic retinopathy can be detected at molecular level

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

Tiny eye implant enables patients to battle glaucoma

Penn Medicine launches CAROT to build novel therapies for retinal and ocular disorders

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News